浅论建立医疗机构使用药品法律许可制度

新修订的《药品管理法》已于2001年12月1日正式实施，这部法律是我国法制建设的又一重大成果，标志着我国药品监督管理依法行政上升到了一个新的高度。但是，这部法律没有建立医疗机构使用药品的法律许可制度。本文就此谈谈粗浅意见。　　医疗机构使用药品现状 新修订的《药品管理法》将与药品流通有关的单位（个人）划分为生产、经营和使用，而处在药品流通领域至关重要的终端环节的医疗机构，其使用药品的现状如何呢？ 一、缺乏药学人员　　就我县近400余个医疗机构而言，除县人民医院、县中医院、县保健院外，其他医疗机构几乎没有…     

Naphyrone: a "legal high" not legal any more

Naphyrone, also known as naphthylpyrovalerone and O-2482, is a cathinone derivative that has been recently advertized for purchase on a number of websites. Naphyrone belongs to a new class of "designer drugs" that has emerged on the drugs abuse market and has gained popularity as the new "legal high." Legal highs have been circulating for a number of years in Europe and are becoming popular in the United States. They are affordable, widely available, legal to use and possess, and legal to supply. This review presents any available information about safety profile, clinical data, analytical profile, and legislation of this legal high, which is not legal any more. Any available information has been collected by various literature search engines and the World Wide Web. The structure of naphyrone is similar to that of pyrovalerone, a monoamine uptake inhibitor. This new designer drug does not have a long history of use, so there is little evidence of its long-term effects or on the risks from its use. Because of its similarity to other cathinone derivatives, naphyrone is likely to share the same risks, such as anxiety, paranoia, and overstimulation of the heart and circulatory system. Naphyrone was classified as a controlled drug under the UK Misuse of Drugs Act of 1971 (Amendment No. 2) Regulation 2010.     

多靶点肽类镇痛药物的研究进展

Mu阿片受体为吗啡和芬太尼等传统阿片类镇痛药物的主要作用靶点。传统的阿片类镇痛药物广泛用于中度和重度疼痛的临床治疗,但长期使用该类药物会引起镇痛耐受和成瘾等副作用,并伴随着眩晕、恶心、呕吐、便秘、瘙痒、呼吸抑制等不良反应,从而限制了其临床应用。近年来,多靶点分子的研究取得重要进展,可对此类药物的镇痛活性与副作用进行有效分离。同时靶向mu阿片受体和其他受体的多靶点分子能产生有效的镇痛活性,并能降低镇痛耐受、成瘾、呼吸抑制和便秘等阿片样副作用,其在高效、低副作用的镇痛新药研发中具有潜在的应用前景。综述多靶点肽类镇痛药物的设计及其药理学活性,为新型肽类镇痛新药的研发提供新的思路。

     

Drug approvals: the US are not lagging behind

What is the burden of paediatric asthma in real terms? Are genetic influences important, and what are the risk factors associated with asthma? Should corticosteroids be incorporated into the treatment of preschool children? How is quality of life (QOL) best assessed in children with asthma? These issues and other problems associated with treating asthma in children were presented and debated at the 5th International Respiratory Forum [ London, UK; November 1996 ].